Epidermal growth factor enhances androgen receptor-mediated bladder cancer progression and invasion via potentiation of AR transactivation

Oncology Reports

Volumn 30, Issue 6, 2013, Pages 2917-2922

  Hsieh, Teng Fu ^a,b   Chen, Chi Cheng ^a   Ma, Wen Lung ^a   Chuang, Wei Min ^a   Hung, Xiao Fan ^a   Tsai, Yi Ru ^a   Lin, Meng Hsueh Amanda ^a   Zhang, Qiaoxia ^c   Zhang, Caixia ^c   Chang, Chawnshang ^a,c   Shyr, Chih Rong ^a  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b TAICHUNG TZU CHI HOSPITAL   (Taiwan)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Androgen receptor; Bladder cancer; Epidermal growth factor; Invasion; Migration

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; ANDROGEN RECEPTOR; BICALUTAMIDE; COMPLEMENTARY DNA; EPIDERMAL GROWTH FACTOR; LENTIVIRUS VECTOR; MITOGEN ACTIVATED PROTEIN KINASE; N [4 (3 BROMOANILINO) 6 QUINAZOLINYL]ACRYLAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

ARTICLE; BLADDER CANCER; BLADDER CARCINOGENESIS; CANCER GROWTH; CANCER INHIBITION; CASTRATION; CELL MIGRATION; CONTROLLED STUDY; DRUG POTENTIATION; DRUG TARGETING; EMBRYO; HORMONE DETERMINATION; HORMONE RECEPTOR INTERACTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TRANSACTIVATION; TUMOR INVASION; VIRAL GENE DELIVERY SYSTEM;

ANDROGENS; ANIMALS; BUTYLHYDROXYBUTYLNITROSAMINE; CARCINOGENESIS; CASTRATION; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; EPIDERMAL GROWTH FACTOR; HUMANS; MALE; MICE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; PHOSPHATIDYLINOSITOL 3-KINASES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION; URINARY BLADDER NEOPLASMS;

EID: 84892423233     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2792     Document Type: Article

References (30)

1. Siegel R, Ward E, Brawley O and Jemal A: Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61: 212-236, 2011.
2. Shariat SF, Sfakianos JP, Droller MJ, Karakiewicz PI, Meryn S and Bochner BH: The effect of age and gender on bladder cancer: a critical review of the literature. BJU Int 105: 300-308, 2010.
3. Fajkovic H, Halpern JA, Cha EK, et al: Impact of gender on bladder cancer incidence, staging, and prognosis. World J Urol 29: 457-463, 2011.
4. Miyamoto H, Yang Z, Chen YT, et al: Promotion of bladder cancer development and progression by androgen receptor signals. J Natl Cancer Inst 99: 558-568, 2007.
5. Imada S, Akaza H, Ami Y, Koiso K, Ideyama Y and Takenaka T: Promoting effects and mechanisms of action of androgen in bladder carcinogenesis in male rats. Eur Urol 31: 360-364, 1997.
6. Heinlein CA and Chang C: The roles of androgen receptors and androgen-binding proteins in nongenomic androgen actions. Mol Endocrinol 16: 2181-2187, 2002.
7. Grivas PD, Day M and Hussain M: Urothelial carcinomas: a focus on human epidermal receptors signaling. Am J Transl Res 3: 362-373, 2011.
8. Kanno N, Nonomura N, Miki T, et al: Effects of epidermal growth factor on the invasion activity of the bladder cancer cell line. J Urol 159: 586-590, 1998.
9. Kawamata H, Azuma M, Kameyama S, Nan L and Oyasu R: Effect of epidermal growth factor/transforming growth factor alpha and transforming growth factor beta 1 on growth in vitro of rat urinary bladder carcinoma cells. Cell Growth Differ 3: 819-825, 1992.
10. Rowinsky EK: The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors. Annu Rev Med 55: 433-457, 2004.
11. Lipponen P and Eskelinen M: Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis. Br J Cancer 69: 1120-1125, 1994.
12. Sauter G, Haley J, Chew K, et al: Epidermal-growth-factor-receptor expression is associated with rapid tumor proliferation in bladder cancer. Int J Cancer 57: 508-514, 1994.
13. Chow NH, Chan SH, Tzai TS, Ho CL and Liu HS: Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clin Cancer Res 7: 1957-1962, 2001.
14. Culig Z, Hobisch A, Cronauer MV, et al: Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 54: 5474-5478, 1994.
15. Ma WL, Hsu CL, Yeh CC, et al: Hepatic androgen receptor suppresses hepatocellular carcinoma metastasis through modulation of cell migration and anoikis. Hepatology 56: 176-185, 2012.
16. Nguyen PL, Swanson PE, Jaszcz W, et al: Expression of epidermal growth factor receptor in invasive transitional cell carcinoma of the urinary bladder. A multivariate survival analysis. Am J Clin Pathol 101: 166-176, 1994.
17. Chow NH, Tzai TS, Lin SN, Chan SH and Tang MJ: Reappraisal of the biological role of epidermal growth factor receptor in transitional cell carcinoma. Eur Urol 24: 140-143, 1993.
18. Zheng Y, Izumi K, Yao JL and Miyamoto H: Dihydrotestosterone upregulates the expression of epidermal growth factor receptor and ERBB2 in androgen receptor-positive bladder cancer cells. Endocr Relat Cancer 18: 451-464, 2011.
19. Brass AL, Barnard J, Patai BL, Salvi D and Rukstalis DB: Androgen up-regulates epidermal growth factor receptor expression and binding affinity in PC3 cell lines expressing the human androgen receptor. Cancer Res 55: 3197-3203, 1995.
20. Migliaccio A, Di Domenico M, Castoria G, et al: Steroid receptor regulation of epidermal growth factor signaling through Src in breast and prostate cancer cells: steroid antagonist action. Cancer Res 65: 10585-10593, 2005.
21. Craft N, Shostak Y, Carey M and Sawyers CL: A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 5: 280-285, 1999.
22. Culig Z, Hobisch A, Cronauer MV, et al: Regulation of prostatic growth and function by peptide growth factors. Prostate 28: 392-405, 1996.
23. Heinlein CA and Chang C: Androgen receptor in prostate cancer. Endocr Rev 25: 276-308, 2004.
24. Putz T, Culig Z, Eder IE, et al: Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines. Cancer Res 59: 227-233, 1999.
25. Chen T, Cho RW, Stork PJ and Weber MJ: Elevation of cyclic adenosine 3',5'-monophosphate potentiates activation of mitogen-activated protein kinase by growth factors in LNCaP prostate cancer cells. Cancer Res 59: 213-218, 1999.
26. Gregory CW, Fei X, Ponguta LA, et al: Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer. J Biol Chem 279: 7119-7130, 2004.
27. Orio F, Terouanne B, Georget V, et al: Potential action of IGF-1 and EGF on androgen receptor nuclear transfer and transactivation in normal and cancer human prostate cell lines. Mol Cell Endocrinol 198: 105-114, 2002.
28. Kassouf W, Dinney CPN, Brown G, et al: Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells. Cancer Res 65: 10524-10535, 2005.
29. Ma WL, Hsu CL, Wu MH, et al: Androgen receptor is a new potential therapeutic target for the treatment of hepatocellular carcinoma. Gastroenterology 135: 947-955, 955.e1-5, 2008.
30. Wu JT, Han BM, Yu SQ, Wang HP and Xia SJ: Androgen receptor is a potential therapeutic target for bladder cancer. Urology 75: 820-827, 2010.